CCLA Investment Management Has $82.64 Million Stake in Agilent Technologies, Inc. (NYSE:A)

Key Points

• CCLA Investment Management increased its stake in Agilent Technologies by 5.6%, holding approximately 706,671 shares valued at $82.64 million at the end of the first quarter.
• Agilent Technologies reported $1.31 EPS for the last quarter, exceeding analysts' expectations by $0.05, with a revenue of $1.67 billion, up 6% year-over-year.
• The company declared a quarterly dividend of $0.248 per share, translating to an annual yield of 0.9% and a dividend payout ratio of 24.44%.

CCLA Investment Management lifted its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 5.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 706,671 shares of the medical research company's stock after buying an additional 37,420 shares during the period. CCLA Investment Management owned about 0.25% of Agilent Technologies worth $82,638,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of A. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company's stock worth $4,279,000 after buying an additional 4,362 shares during the last quarter. Prudential PLC raised its holdings in Agilent Technologies by 16.0% during the fourth quarter. Prudential PLC now owns 73,273 shares of the medical research company's stock worth $9,843,000 after acquiring an additional 10,128 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Agilent Technologies by 8.3% during the first quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company's stock valued at $3,606,000 after purchasing an additional 2,371 shares during the last quarter. Alps Advisors Inc. boosted its position in Agilent Technologies by 29.5% during the first quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company's stock valued at $1,563,000 after purchasing an additional 3,040 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Agilent Technologies by 18.9% in the fourth quarter. Russell Investments Group Ltd. now owns 322,224 shares of the medical research company's stock valued at $43,289,000 after purchasing an additional 51,144 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. UBS Group reduced their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a report on Thursday, May 29th. Barclays lifted their target price on Agilent Technologies from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research note on Tuesday, June 24th. Evercore ISI increased their price target on Agilent Technologies from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Wells Fargo & Company cut their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a report on Thursday, April 17th. Finally, Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $139.77.

Agilent Technologies Trading Down 1.1%

NYSE A opened at $113.51 on Friday. The company has a market cap of $32.24 billion, a price-to-earnings ratio of 28.03, a price-to-earnings-growth ratio of 3.44 and a beta of 1.22. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The business's fifty day moving average is $117.08 and its 200 day moving average is $120.64.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.05. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. Agilent Technologies's revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.22 earnings per share. As a group, sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 23rd. Investors of record on Tuesday, July 1st were paid a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Tuesday, July 1st. Agilent Technologies's dividend payout ratio (DPR) is currently 24.44%.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the transaction, the chief executive officer directly owned 37,448 shares of the company's stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.